Clin2
NCT07202884Possibly a fitRecruiting

Orforglipron for Women with Stress Incontinence and Overweight

Urinary Incontinence,Stress

Treatments studied

Part of Kidney & urinary, Women’s health & pregnancy clinical trials.

This study tests an oral medication called orforglipron to see if it helps women with stress urinary incontinence who are also overweight or have obesity. The medicine may reduce leaking episodes and also help with weight loss.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,000 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have a body mass index (BMI) of 27 or higher (classified as overweight or obesity).
  • You must have been diagnosed with stress urinary incontinence—involuntary urine leakage during coughing, sneezing, laughing, or physical activity.
  • You cannot have had any previous surgery for urinary incontinence or bladder Botox injections.
  • It must be at least one year since you gave birth, if applicable.
  • Your weight has been stable (no change of more than 11 pounds) in the last 3 months, and you haven't used weight-loss medications in the last 6 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07223593Recruiting· Phase 3
Orforglipron for peripheral artery disease with leg pain

This trial tests a new oral medication called orforglipron to see if it can improve walking distance in people with peripheral artery disease (PAD) who have leg pain when walking. It may be a good option if you have PAD and your walking is limited by leg cramping, not other health issues.

Birmingham, Alabama
NCT07654361Recruiting· Phase 3
A new pill for weight loss in obesity and overweight

This study tests an investigational pill called aleniglipron to see if it helps people with obesity or overweight who also have a weight-related health problem (like high blood pressure) lose weight safely. It is a Phase 3 trial, meaning it is in the final stages before seeking approval.

Birmingham, Alabama
NCT07667803Recruiting· Phase 3
Study of elecoglipron for weight loss in obesity or overweight

This trial tests an investigational drug called elecoglipron to see if it helps people with obesity or overweight lose weight. It may be an option if you have a high body mass index or weight-related health issues like high blood pressure or prediabetes.

Birmingham, Alabama
NCT07770841Recruiting· Phase 3
Oral medication for weight loss study

This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.

Birmingham, Alabama
NCT06672939Recruiting· Phase 3
Orforglipron for Weight Loss in Teens

This study tests a once-daily pill (orforglipron) to help adolescents with obesity or overweight plus related health problems lose weight. It offers a new option for teens who have struggled to lose weight with diet and exercise alone.

Oxnard, California
NCT07790861Not yet recruiting· Phase 3
Study of an oral weight loss medication in Chinese adults with overweight or obesity

This trial tests an investigational oral medication to help Chinese adults with overweight or obesity, plus related health issues, lose weight. It focuses on improving weight loss and overall health in this group.

Chengdu

Hear when a new Urinary Incontinence,Stress trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.